Methods of treating allergy using anti-bet v 1 antibodies
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsAmanda Atanasio, Gary Herman, Meagan P. O'Brien, Jamie M. Orengo, Lorah Perlee
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods for treating, preventing, or ameliorating one or more symptoms of birch allergy or allergic disease in a subject by administering to the subject an antibody or antigen-binding fragment thereof that binds Bet v 1, or a cocktail of antibodies or antigen-binding fragments thereof that bind Bet v 1.
Claims47
A method of improving one or more symptoms of birch pollen-related oral allergy syndrome in a subject in need thereof, the method comprising:
- administering to the subject a pharmaceutical composition comprising an anti-Bet v 1 antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain complementarity determining region (HCDR)1 comprising the amino acid sequence of SEQ ID NO:22, an HCDR2 comprising the amino acid sequence of SEQ ID NO:23, an HCDR3 comprising the amino acid sequence of SEQ ID NO:24, a light chain complementarity determining region (LCDR)1 comprising the amino acid sequence of SEQ ID NO:26, an LCDR2 comprising the amino acid sequence of GAS, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:28;
- wherein the pharmaceutical composition is administered to the subject once every 8 weeks or less frequently at a dose of about 150 mg to about 300 mg of the anti-Bet v 1 antibody or antigen-binding fragment thereof;
- wherein the subject has an allergy to birch pollen and has oral allergy syndrome.
A method of improving one or more symptoms of birch pollen-related oral allergy syndrome in a subject in need thereof, the method comprising administering to the subject a first pharmaceutical composition comprising a first anti-Bet v 1 antibody or antigen-binding fragment thereof and a second pharmaceutical composition comprising a second anti-Bet v 1 antibody or antigen-binding fragment thereof,
- wherein the first anti-Bet v 1 antibody or antigen-binding fragment thereof comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO:22, an HCDR2 comprising the amino acid sequence of SEQ ID NO:23, an HCDR3 comprising the amino acid sequence of SEQ ID NO:24, an LCDR1 comprising the amino acid sequence of SEQ ID NO:26, an LCDR2 comprising the amino acid sequence of GAS, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:28, wherein the first anti-Bet v 1 antibody or antigen-binding fragment thereof is administered at a dose of about 150 mg to about 300 mg;
- wherein the second anti-Bet v 1 antibody or antigen-binding fragment thereof comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO:2, an HCDR2 comprising the amino acid sequence of SEQ ID NO:3, an HCDR3 comprising the amino acid sequence of SEQ ID NO:4, an LCDR1 comprising the amino acid sequence of SEQ ID NO:6, an LCDR2 comprising the amino acid sequence of DAS, and an LCDR3 comprising the amino acid sequence of SEQ ID NO:8, wherein the second anti-Bet v 1 antibody or antigen-binding fragment thereof is administered at a dose of about 150 mg to about 300 mg;
- wherein the first pharmaceutical composition and the second pharmaceutical composition are administered to the subject once every 8 weeks or less frequently;
- and
- wherein the subject has an allergy to birch pollen and has oral allergy syndrome.
Dependencies are inferred from the claim text.